ARS Pharmaceuticals EBIT 2020-2025 | SPRY

ARS Pharmaceuticals ebit from 2020 to 2025. Ebit can be defined as earnings before interest and taxes.

ARS Pharmaceuticals EBIT 2020-2025 | SPRY

ARS Pharmaceuticals ebit from 2020 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$77.5B
Zoetis (ZTS)$65.6B
Daiichi Sankyo, - (DSNKY)$46.1B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$32B
Sandoz Group AG (SDZNY)$25.2B
Summit Therapeutics (SMMT)$19.6B
Merck (MKKGY)$16.6B
Shionogi (SGIOY)$14.4B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.5B
Corcept Therapeutics (CORT)$7.4B
Madrigal Pharmaceuticals (MDGL)$7.3B
Stevanato Group S.p.A (STVN)$7.3B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Procaps Group, S.A (PROCF)$3.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B